About this page
Insider trades reported on SEC Form 4: when the people who run a company buy or sell its shares with their own money.
How to read it
- Form 4
- The form a company insider (officer, director or owner of more than 10%) must file with the SEC within two business days of buying or selling the company's shares.
- Buy (P) and Sell (S)
- Open-market purchases and sales. Gifts, option exercises and automatic tax withholding are left out because they say little about what the insider thinks.
- Value
- Shares times price, as reported on the filing.
- 10b5-1
- A trade made under a plan set up in advance. Planned sales are common and usually say less than an unplanned purchase.
- Late filing
- A Form 4 filed more than two business days after the trade.
- Vs. S&P 500
- How the stock did after the trade minus how the overall market did in the same weeks.
A real example
In January 2016, when bank stocks were falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares with his own money, worth about $26 million. His Form 4 made the purchase public within days, and investors read it as a strong sign of confidence.
Explain it like I'm 13
If the coach of a team bets his own allowance that his team will win, that tells you something. A Form 4 is the note a company boss must hand in whenever he buys or sells his own company's shares, so everyone can see it.
Data from public SEC filings and congressional reports. Information, not investment advice. Check every number against the filing linked on the page.
Immunome Inc. (IMNM): Insider Trades and Fund Holdings
In the past 12 months, Immunome Inc. insiders reported no open-market purchases and 15 sales worth $16.0M; 15 of the sales were reported as made under a 10b5-1 trading plan.
Timeline: news and trades
Company filings (8-K), insider trades, notices of planned sales (Form 144), Congress trades and fund moves in the past year, newest first.
- Oct 5, 2026NewsCompany reported: Signed a material agreement
- Sep 11, 2026Insider saleChief Scientific Officer Jack Higgins sold $334,224 under a 10b5-1 plan
- Sep 11, 2026Planned saleHiggins Jack (officer) filed notice to sell about $334,224 around Sep 11, 2026
- Aug 12, 2026Insider saleDirector Isaac Barchas sold $301,058 under a 10b5-1 plan
- Aug 11, 2026Insider saleDirector Isaac Barchas sold $1.6 million under a 10b5-1 plan
- Aug 10, 2026Insider saleDirector Isaac Barchas sold $263,959 under a 10b5-1 plan
- Aug 7, 2026Insider saleDirector Isaac Barchas sold $397,363 under a 10b5-1 plan
- Aug 6, 2026Insider saleDirector Isaac Barchas sold $543,090 under a 10b5-1 plan
- Aug 4, 2026Insider saleCHIEF BUSINESS OFFICER Kinney Horn sold $2.3 million under a 10b5-1 plan
- Jul 7, 2026Insider saleCHIEF BUSINESS OFFICER Kinney Horn sold $27,300 under a 10b5-1 plan
- Jul 7, 2026Insider saleDirector Isaac Barchas sold $409,125 under a 10b5-1 plan
- Jul 6, 2026Insider saleDirector Isaac Barchas sold $2 million under a 10b5-1 plan
- Jul 2, 2026Insider saleChief Medical Officer Robert Lechleider sold $1.2 million under a 10b5-1 plan
- Jul 2, 2026Insider saleDirector Isaac Barchas sold $2.3 million under a 10b5-1 plan
- Jun 30, 2026Insider saleDirector Isaac Barchas sold $2.1 million under a 10b5-1 plan
- Jun 30, 2026FundRenaissance Technologies added 264% in Q2 2026 (13F filed Aug 13, 2026)
- Jun 25, 2026Insider saleChief Medical Officer Robert Lechleider sold $1.1 million under a 10b5-1 plan
- Jun 15, 2026Insider saleCFO Max Rosett sold $1.1 million under a 10b5-1 plan
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Sep 15, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Sep 15 | Jack HigginsChief Scientific Officer | ▼ SELL10b5-1 | $334K |
| Aug 12 | Isaac BarchasDirector | ▼ SELL10b5-1 | $1.63M |
| Aug 12 | Isaac BarchasDirector | ▼ SELL10b5-1 | $301K |
| Aug 12 | Isaac BarchasDirector | ▼ SELL10b5-1 | $264K |
| Aug 10 | Isaac BarchasDirector | ▼ SELL10b5-1 | $543K |
| Aug 10 | Isaac BarchasDirector | ▼ SELL10b5-1 | $397K |
| Aug 6 | Kinney HornCHIEF BUSINESS OFFICER | ▼ SELL10b5-1 | $2.27M |
| Jul 9 | Kinney HornCHIEF BUSINESS OFFICER | ▼ SELL10b5-1 | $27K |
| Jul 7 | Isaac BarchasDirector | ▼ SELL10b5-1 | $2.00M |
| Jul 7 | Robert LechleiderChief Medical Officer | ▼ SELL10b5-1 | $1.24M |
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Jack Higgins | Chief Scientific Officer | 0 | $0 | 1 | $334K |
| Isaac Barchas | Director | 0 | $0 | 9 | $9.94M |
| Kinney Horn | CHIEF BUSINESS OFFICER | 0 | $0 | 2 | $2.30M |
| Robert Lechleider | Chief Medical Officer | 0 | $0 | 2 | $2.34M |
| Max Rosett | CFO | 0 | $0 | 1 | $1.09M |
Buybacks and executive pay
| Year | CEO pay reported | CEO pay "actually paid" | Value of $100 invested |
|---|---|---|---|
| 2025 | $7.68M | $28.1M | n/a |
| 2024 | $9.23M | $8.41M | n/a |
From the company's XBRL data filed with the SEC. "Actually paid" is the SEC's pay-versus-performance measure, which counts changes in the value of stock awards. "Value of $100 invested" is the company's cumulative shareholder return as reported, usually measured from five years earlier. See all buybacks and CEO pay across companies.
A All 15 insider trades reported on time. How it is graded
Tracked funds that report IMNM
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 251,102 | $5.32M | ▲ +264.4% |
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →